---
schema_version: "secwatch.filing_event.v1"
accession: "0001214659-26-000377"
form_type: "8-K"
ticker: "EBRCZ"
cik: "0001347123"
company_name: "EBR Systems, Inc."
filed_at: "2026-01-13T23:59:59+00:00"
generated_at: "2026-05-16T10:38:13.584096+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# EBR Systems reports Q4 2025 preliminary rev ~$900K; WiSE implants double QoQ, clinical studies advance

## Summary
- Preliminary Q4 revenue $870K-$935K; FY2025 revenue $1,552K-$1,617K (unaudited, subject to audit adjustments).
- Commercial WiSE implants doubled QoQ to 18 in Q4, reaching 30 total for the year; 9 new purchase agreements signed.
- WiSE-UP post-approval study enrolled 4 patients; TLC-AU feasibility study enrolled first patient in Australia.
- 11 additional physicians trained in Q4, bringing total trained to 33 across 21 centers.

## SEC filing metadata
- accession: 0001214659-26-000377
- form_type: 8-K
- ticker: EBRCZ
- cik: 0001347123
- company_name: EBR Systems, Inc.
- filed_at: 2026-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347123/000121465926000377/0001214659-26-000377-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347123/000121465926000377/b1122638k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001214659-26-000377
- JSON: https://secwatch.observer/filing/0001214659-26-000377.json
- Plain text: https://secwatch.observer/filing/0001214659-26-000377.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.